News | Heart Valve Technology | June 27, 2017

Mitralign Announces First European Subject Enrolled in SCOUT II Study of Trialign System

Investigational device offers minimally invasive option for transcatheter tricuspid repair

Mitralign Announces First European Subject Enrolled in SCOUT II Study of Trialign System

June 27, 2017 — Mitralign Inc. announced the commencement of its SCOUT II study in Europe, with the Trialign System for the transcatheter treatment of patients suffering from tricuspid regurgitation.

“We are pleased to be the first center in Europe to commence enrolling in SCOUT II,” commented Azeem Latib, M.D., interventional cardiologist at San Raffaele Scientific Institute, Milan, Italy. “This is an exciting therapy which allows us to deliver a minimally invasive solution to a group of patients who have limited treatment options. The procedure was a great success, as we saw acute reduction in tricuspid regurgitation and the patient was able to go home shortly thereafter.”

The Trialign System is an investigational device and is exclusively for clinical investigation. It is limited by federal (or United States) law to investigational use only. It is not available for sale or commercial distribution. The Trialign System is currently enrolling in the SCOUT I Early Feasibility Study and the SCOUT II CE Mark Study.

Six-month data from SCOUT I was presented at the Transcatheter Valve Therapies (TVT) conference, June 15-17 in Chicago.

Watch the VIDEO “Transcatheter Tricuspid Valve Repair and Replacement Technologies,” an interview with Rebecca Hahn, M.D., at ASE 2017.

For more information: www.mitralign.com


Related Content

News | Cardiovascular Clinical Studies

February 21, 2024 — An 80-year-old woman from Frankenmuth, Michigan is the first Henry Ford Health structural heart ...

Home February 21, 2024
Home
News | Cardiovascular Clinical Studies

February 15, 2024 — Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and ...

Home February 15, 2024
Home
News | Cardiovascular Clinical Studies

January 3, 2024 — Cardionomic, Inc., a Minneapolis medical device company, is pleased to announce the completion of ...

Home January 03, 2024
Home
News | Cardiovascular Clinical Studies

December 19, 2023 — Peerbridge Health has announce the successful completion and findings of its prospective ...

Home December 19, 2023
Home
News | Cardiovascular Clinical Studies

December 14, 2023 — Published results of a large, national heart attack study show that patients with a life-threatening ...

Home December 14, 2023
Home
News | Cardiovascular Clinical Studies

December 11, 2023 — A world without cardiovascular disease (CVD) is possible, yet millions of lives are lost prematurely ...

Home December 11, 2023
Home
News | Cardiovascular Clinical Studies

December 8, 2023 — Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac ...

Home December 08, 2023
Home
News | Cardiovascular Clinical Studies

November 29, 2023 — Inari Medical, Inc., a medical device company with a mission to treat and transform the lives of ...

Home November 29, 2023
Home
Subscribe Now